Daiichi Sankyo, Virtici and Celdara Medical enter high potential therapeutics collaboration
To further strengthen Daiichi Sankyo pipeline
Japanese pharmaceutical manufacturer Daiichi Sankyo has entered into a collaboration with Virtici and Celdara Medical to investigate novel therapeutic candidates and strengthen its pipeline across multiple therapeutic areas.
US-based Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets. The collaboration aims to accelerate the time from discovery to development with the potential to deliver treatments that address significant unmet medical needs. Funding is channelled into the most promising targets to drive early research before moving into larger scale clinical development.
‘This collaboration strengthens our ability to access potential breakthrough innovation, and demonstrates our continued commitment to working with partners at the forefront of science,’ said Mahmoud Ghazzi, Global Head of Development at Daiichi Sankyo.
‘By augmenting in-house research and other development avenues, these focused, exclusive, indication-targeted partnerships can accelerate medical innovations into the clinic and ultimately to patients.’
Neil Fanger, President and Chief Executive at Virtici, said: ‘Using our unique model, infrastructure and capabilities, we can help further advance Daiichi Sankyo's strong track record of innovative drug development.’
‘Daiichi Sankyo's impressive capabilities, global reach, and open, collaborative culture make them ideal partners,’ added Jake Reder, President and Chief Executive of Celdara Medical.
